Myriad Genetics, Inc.
MYGNNASDAQHealthcare● Active
$4.39
$-0.18(-3.94%)
Market Cap$414627598
P/E Ratio—
52W High$8.59
52W Low$3.53
Myriad Genetics, Inc. (MYGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MYGN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.09
Est. -$0.06 · -50.0%
Revenue
$0.20B
Est. $0.20B · -1.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS
MYGN reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.03 | — | — | — | $0.21B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.06 | -$0.09 | -50.0% | $0.20B | $0.20B | -1.0% |
| ▲ Q1 FY2026 | Feb 23, 2026 | -$0.02 | $0.04 | +300.0% | $0.21B | $0.21B | +1.1% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -$0.01 | -$0.13 | -1200.0% | $0.21B | $0.21B | -0.6% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.01 | $0.05 | +600.0% | $0.21B | $0.21B | +3.8% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.05 | -$0.03 | +40.0% | $0.20B | $0.21B | -7.5% |
| — Q1 FY2025 | Feb 24, 2025 | $0.03 | $0.03 | +0.0% | $0.21B | $0.21B | +0.1% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.02 | $0.06 | +215.8% | $0.21B | $0.21B | -0.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.09
EPS Est.
-$0.06
EPS Surpr.
-50.0%
Revenue
$0.20B
Q1 FY2026
Feb 23, 2026Beat
EPS Actual
$0.04
EPS Est.
-$0.02
EPS Surpr.
+300.0%
Revenue
$0.21B
Q4 FY2025
Nov 3, 2025Miss
EPS Actual
-$0.13
EPS Est.
-$0.01
EPS Surpr.
-1200.0%
Revenue
$0.21B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.05
EPS Est.
-$0.01
EPS Surpr.
+600.0%
Revenue
$0.21B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.03
EPS Est.
-$0.05
EPS Surpr.
+40.0%
Revenue
$0.20B
Q1 FY2025
Feb 24, 2025
EPS Actual
$0.03
EPS Est.
$0.03
EPS Surpr.
+0.0%
Revenue
$0.21B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.06
EPS Est.
$0.02
EPS Surpr.
+215.8%
Revenue
$0.21B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.04 | $0.04 | $0.04 | 2 |
| Q3 FY2028 | $0.08 | $0.08 | $0.08 | 2 |
| Q2 FY2028 | $0.07 | $0.07 | $0.07 | 2 |
| Q1 FY2028 | $-0.01 | $-0.01 | $-0.01 | 2 |
| Q4 FY2027 | $0.10 | $0.10 | $0.10 | 1 |
| Q3 FY2027 | $0.07 | $0.07 | $0.07 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.3B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -50.0% | $4.94 | $5.03 | +1.82% |
| ▲ Q1 FY2026 | Feb 23, 2026 | +300.0% | $4.29 | $4.38 | +2.10% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -1200.0% | $8.04 | $8.18 | +1.74% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +600.0% | $3.98 | $3.87 | -2.76% |
| ▲ Q2 FY2025 | May 6, 2025 | +40.0% | $7.70 | $7.27 | -5.58% |
| ▲ Q1 FY2025 | Feb 24, 2025 | +0.0% | $14.18 | $13.78 | -2.82% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +215.8% | $17.57 | $17.67 | +0.57% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +509.0% | $25.84 | $25.96 | +0.46% |
Q2 FY2026+1.82%
Report Date
May 5, 2026
EPS Beat/Miss
-50.0%
Price Before
$4.94
Price After
$5.03
Q1 FY2026+2.10%
Report Date
Feb 23, 2026
EPS Beat/Miss
+300.0%
Price Before
$4.29
Price After
$4.38
Q4 FY2025+1.74%
Report Date
Nov 3, 2025
EPS Beat/Miss
-1200.0%
Price Before
$8.04
Price After
$8.18
Q3 FY2025-2.76%
Report Date
Aug 5, 2025
EPS Beat/Miss
+600.0%
Price Before
$3.98
Price After
$3.87
Q2 FY2025-5.58%
Report Date
May 6, 2025
EPS Beat/Miss
+40.0%
Price Before
$7.70
Price After
$7.27
Q1 FY2025-2.82%
Report Date
Feb 24, 2025
EPS Beat/Miss
+0.0%
Price Before
$14.18
Price After
$13.78
Q4 FY2024+0.57%
Report Date
Nov 7, 2024
EPS Beat/Miss
+215.8%
Price Before
$17.57
Price After
$17.67
Q3 FY2024+0.46%
Report Date
Aug 6, 2024
EPS Beat/Miss
+509.0%
Price Before
$25.84
Price After
$25.96
Avg Beat Reaction-1.34%
Avg Miss Reaction+1.78%
Beat Rate6 / 8 quarters
Largest Move-5.58% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MYGN ends December
Myriad Genetics, Inc. (MYGN) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.09 — missing the analyst consensus of $-0.06 by -50.0%. The next MYGN earnings date is expected around September 1, 2026.
Each quarter, investors track MYGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MYGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MYGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MYGN earnings · 5 questionsMyriad Genetics, Inc.'s next earnings report is expected around September 1, 2026. MYGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MYGN historically reports after market close (AMC).
MYGN earnings datewhen is MYGN earningsMYGN next earnings datewhen does MYGN report earningsMYGN earnings calendar
▸ Source: FMP · Myriad Genetics, Inc. SEC filings · US GAAP · Myriad Genetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026